Rapafusyn Pharmaceuticals, Inc.
Rapafusyn is pioneering RapaGluesTM, a unique modality of non-degrading molecular glues designed to target previously intractable proteins. The company's mission is to develop transformative therapies for patients with limited or no treatment options, focusing on challenging intracellular proteins using its proprietary platform. Their lead program targets Acute Kidney Injury (AKI), a severe complication with no current approved therapies, by inhibiting ENT1 to preserve extracellular adenosine levels and mitigate ischemia/reperfusion injury. The company is supported by a team of experienced drug development leaders and is actively engaged in partnerships and collaborations to expand its innovative drug discovery efforts.
Industries
Nr. of Employees
small (1-50)
Rapafusyn Pharmaceuticals, Inc.
Baltimore, Maryland, United States, North America
Products
Selective ENT1 inhibitor — clinical development candidate for prevention of ischemia/reperfusion-driven acute kidney injury
A potent and selective inhibitor of equilibrative nucleoside transporter 1 developed to preserve extracellular adenosine and mitigate ischemia/reperfusion-driven renal injury; supported by preclinical efficacy in relevant models and advanced toward clinical development.
Selective ENT1 inhibitor — clinical development candidate for prevention of ischemia/reperfusion-driven acute kidney injury
A potent and selective inhibitor of equilibrative nucleoside transporter 1 developed to preserve extracellular adenosine and mitigate ischemia/reperfusion-driven renal injury; supported by preclinical efficacy in relevant models and advanced toward clinical development.
Services
Discovery collaborations and partnering
Collaborative research and partnership arrangements to apply the integrated discovery platform for target discovery, hit identification and lead generation.
Business development and alliance management services
Structuring strategic collaborations, licensing agreements and accelerator engagements to advance programs and secure external support.
Discovery collaborations and partnering
Collaborative research and partnership arrangements to apply the integrated discovery platform for target discovery, hit identification and lead generation.
Business development and alliance management services
Structuring strategic collaborations, licensing agreements and accelerator engagements to advance programs and secure external support.
Expertise Areas
- Induced-proximity small-molecule therapeutics (non-degrading)
- Macrocycle library design and medicinal chemistry
- DNA-encoded library discovery and screening
- Target identification and validation for intracellular and transporter proteins
Key Technologies
- Induced-proximity small-molecule design
- Macrocycle synthesis and screening
- DNA-encoded libraries (DEL)
- Arrayed small-molecule microarrays